Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application

British Journal of Clinical Pharmacology

Volumn 46, Issue 1, 1998, Pages 5-10

  Kirchner, G I ^a   Franzke, A ^a   Buer, J ^a   Beil, W ^a   Probst Kepper, M ^a   Wittke, F ^a   Overmann K ^a   Lassmann, S ^a   Hoffmann, R ^a   Kirchner, H ^a   Ganser, A ^a   Atzpodien, J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Interleukin 2; Pharmacokinetics; Soluble interleukin 2 receptor; Subcutaneous

Indexed keywords

INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; METASTASIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; BIOLOGICAL AVAILABILITY; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 7144226585     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00036.x     Document Type: Article

References (35)

1. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897.
2. Atzpodien J, Körfer A, Franks C, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet 1990; 335: 1509-1512.
3. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. J Exp Med 1982; 155: 1823-1841.
4. Lotze MT, Grimm EA, Mazumder EA, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumour by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981; 41: 4420-4425.
5. Atzpodien J, Körfer A, Evers P, et al. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 1990; 2: 18-26.
6. Atzpodien J, Poliwoda H, Kirchner H. Alpha-interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitilized patients. Sem Oncol 1991; 18: 108.
7. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on a outpatient basis. J Clin Oncol 1992; 10: 1119.
8. Thompson JA, Lee DJ, Cox WW, et al. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 1987; 47: 4202-4207.
9. Konrad MW, Hemstreet G, Hersh EM, et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 1990; 50: 2009-2017.
10. Gustavson LE, Nadeau RW, Oldfield NF. Pharmacokinetics of Teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer. J Biol Res Modif 1989; 8: 440-449.
11. Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM. Serum levels of low affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 1989; 29: 261-269.
12. Rubin LA, Kurmann CC, Fritz ME, et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172-3177.
13. Smith KA. Interleukin-2: inception, impact and implications. Sci 1988; 240: 1170-1176.
14. Lassalle P, Sergant M, Delneste Y, Gosset P, Wallaert B, Zandecki M. Levels of soluble IL-2 receptor in plasma from asthmatics. Correlations with blood eosinophilia, lung function, and corticosteroid therapy. Clin Exp Immunol 1992; 87: 266-271.
15. Lopez-Hänninen E, Körfer A, Hadam M, et al. Biological monitoring of low-dose interleukin-2 in humans: soluble interleukin. 2 receptors, cytokines, and cell surface phenotypes, Cancer Res 1991; 50: 6312-6316.
16. Waldmann T. The IL-2/IL-2-receptor system: a target for rational immune intervention. Immunol Today 1993; 14: 264-270.
17. Noguchi M, Yoshiaki N, Russel SM, et al. Interleukin-2 receptor gamma-chain: a functional component of the interleukin-7 receptor. Science 1993; 262: 1877-1880.
18. Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Soluble interleukin-2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells. Cytokine 1994; 6: 358-364.
19. Heinzel G, Woloszczak R, Thomann P. TopFit Version 2.0, Pharmacokinetic and pharmacodynamic data analysis system for the PC. Dr. Karl Thomae: Stuttgart; G. Fischer: New York, 1993.
20. Ettinghausen SE, Rosenberg SA. Immunotherapy of inurine sarcomas using lymphokine activated killer cells: optimisation of the schedule and route of administration of recombinant interleukin-2. Cancer Res 1986; 46: 2784-2792.
21. Stute N, Furman WL, Schell M, Evans WE. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. J Pharm Sci 1995; 84: 824-828.
22. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in children. Blood 1992; 79: 2849-2854.
23. Ostenstad B. Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer. Acta-Oncol 1992; 31: 413-415.
24. Mueller AR, Platz KP, Wiehe I, et al. Cytokine pattern in patients with infections after liver transplantation. Transpl Int 1996; Supplement; 1: S126-S131.
25. Kaden J, Schutze B, May G. A critical analysis of soluble interleukin-2 receptor levels in kidney allograft recipients. Transpl Int 1996; 9(Suppl 1): S63-S67.
26. Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumour markers in multiple myeloma. Cancer Detect Prev 1996; 20 (1): 52-56.
27. Kawatani T, Endo A, Tajima F, Ooi S, Kawasaki H. Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders. Int J Hematol 1997; 65: 123-128.
28. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEBJ 1991; 5: 2567-2574.
29. Jacques Y, Le Mauff B, Boeffard F, Godard A, Soulillou JP. A soluble interleukin-2 receptor produced by a normal alloreactive human T cell clone binds interleukin-2 with low affinity. J Immunol 1987; 139: 2308-2316.
30. Pizzolo G, Vincenzi C, Vinante F, et al. Highly concentrated urine-purified tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro. Cell Immunol 1992; 141: 253-259.
31. Kondo N, Kondo S, Shimizu A, Honjo T, Hamuro J. A soluble 'Anchorminus' interleukin-2 receptor suppress in vitro interleukin-2 mediated immune response. Immunol Lett 1988; 19: 299-308.
32. Josimovicz-Alasevic O, Herrmann T, Diamantstein T. Demonstration of two distinct forms of released low-affinity type interleukin-2 receptors. Eur J Immunol 1988; 18: 1855-1857.
33. Chilosi M, Semenzato G, Cetto A, et al. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant α-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987; 70: 530-1535.
34. Symons JA, Wood NC, Di Giovine FS, Dutf GW. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-2 and IL-2 inhibition. J Immunol 1988; 141: 2612-2618.
35. Treiger BF, Leonard WJ, Svetlik P, Rubin LA, Nelson DK, Greene WC. A secreted form of the human interleukin-2 receptor encoded by an 'anchor minus' cDNA. J Immunol 1986; 136: 4099-4105.